|
A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - BIND Biosciences; Myriad Genetics |
Research Funding - Abbvie; Genentech; PharmaMar |
Travel, Accommodations, Expenses - Genentech; Myriad Genetics; Myriad Genetics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech/Roche; Novartis; Verastem |
Research Funding - Genentech/Roche (Inst) |
Travel, Accommodations, Expenses - Genentech/Roche; Novartis |